Clinical Trial Update: Extension Study of ECU-MG-301 to Evaluate Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis [Phase 3]

View source ↗

Summary

Phase 3 extension study assessing safety and efficacy of eculizumab in refractory generalized myasthenia gravis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Myasthenia Gravis

Drugs mentioned

• Eculizumab (eculizumab)

Snippet

Sponsor: Alexion Pharmaceuticals, Inc. | Conditions: Refractory Generalized Myasthenia Gravis | Phase 3 | Status: COMPLETED | Results posted: 2020-02-05